Jefferies reiterates Compass Pathways stock rating on trial data

Compass Pathways (CMPS) reiterated 26-week Study ’006 efficacy data for COMP360 (two upfront oral psilocybin doses) for treatment-resistant depression, building on prior Phase III results from Study ’005. Jefferies maintained a $18.00 Buy target, while Canaccord lifted to $20.00 and TD Cowen set $29.00, with trial enrollment of 581 participants and expectations for FDA NDA completion in Q4 2026 and potential approval around late-2026/1H 2027 (priority review voucher support). Despite a ~9% pullback this week, shares are still up 288% over the past year to $12.18, reinforcing a constructive risk/reward as safety/tolerability data is presented.

Analysis

CMPS is moving from “story stock” to a genuine regulatory optionality trade. The key market mechanism is not near-term revenue but the probability-weighted path to a differentiated depression franchise: if the label is clean and dosing remains infrequent, payer economics could look more like a durable specialty drug than a one-off psychedelic experiment. That said, the stock has already discounted a meaningful share of success, so incremental upside now depends on de-risking rather than just more efficacy prints.

The biggest competitive implication is for JNJ’s Spravato, but the real pressure may show up in the economics of treatment delivery. A lower-frequency regimen could shift value away from clinic throughput and toward drug exclusivity, which matters for reimbursement and provider adoption. If that thesis holds, CMPS can capture share in treatment-resistant depression without needing to “win” on convenience alone; the more important question is whether prescribers and payers will tolerate the monitoring burden and whether the FDA treats psilocybin as a narrowly controlled specialty asset.

Over the next 1-3 months, this likely trades as a sentiment/name-risk stock rather than on fundamentals, so post-data fades are likely unless management narrows the approval timeline or secures a clearer commercialization path. The contrarian view is that the market is underestimating regulatory friction: scheduling, REMS-like constraints, and label limitations could delay broad access even if approval arrives on time. What would falsify the bullish case is any signal that the FDA wants another efficacy study, that safety/tolerability degrades on repeat dosing, or that the launch slips beyond first-half 2027.

Key Decisions for Investors

• Long CMPS only as a small event-driven position, preferably on pullbacks after hype fades; target 12-18 month horizon with upside tied to regulatory de-risking, not quarterly fundamentals.
• Use a defined-risk structure instead of outright equity: buy CMPS 2027 call spreads to express approval optionality while capping downside if FDA timing slips.
• Do not short JNJ as a direct hedge; if you want a relative-value expression, use a very small CMPS/JNJ pair only as a sentiment hedge, since Spravato is too diversified a business to move the stock materially.
• Set an alert on any FDA/CMC/label commentary from CMPS; if management hints at additional studies or a more restrictive launch path, reduce exposure immediately.
• For faster money, wait for the next pullback rather than chase strength; after a 12-month rerating, the risk/reward is better as a volatility-buying opportunity than as a momentum long.